Zenas Biopharma, Common Etf Profile
| ZBIO Etf | USD 10.44 2.01 16.14% |
Performance0 of 100
| Odds Of DistressOver 52
|
Zenas BioPharma, is selling at 10.44 as of the 22nd of November 2024; that is 16.14 percent decrease since the beginning of the trading day. The etf's open price was 12.45. Zenas BioPharma, has 52 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Zenas BioPharma, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of October 2024 and ending today, the 22nd of November 2024. Click here to learn more.
IPO Date 13th of September 2024 | Category Healthcare |
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States. More on Zenas BioPharma, Common
Moving against Zenas Etf
Zenas Etf Highlights
| CEO Board | MBA Moulder |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Average Analyst Recommendation Analysts covering Zenas BioPharma, report their recommendations after researching Zenas BioPharma,'s financial statements, talking to executives and customers, or listening in on Zenas BioPharma,'s conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Zenas BioPharma, Common. The Zenas consensus assessment is calculated by taking the average forecast from all of the analysts covering Zenas BioPharma,. | |
| Date | 31st of December 2023 |
| Total Current Liabilities | 23.26 Million |
| Total Stockholder Equity | (225.72 Million) |
| Name | Zenas BioPharma, Inc. Common Stock |
| Currency Code | USD |
| Fiscal Year End | December |
| Stock Based Compensation | 3.5 Million |
| Industry | Biotechnology |
| Property Plant And Equipment Net | 1.01 Million |
| Begin Period Cash Flow | 67.3 Million |
| Accounts Payable | 5.4 Million |
| Cash | 56.86 Million |
| Non Current Assets Total | 8.38 Million |
| Non Currrent Assets Other | 186,000 |
| Long Term Debt | 20.3 Million |
| Code | ZBIO |
| Total Cash From Financing Activities | 20.12 Million |
| End Period Cash Flow | 56.94 Million |
Zenas BioPharma, Common [ZBIO] is traded in USA and was established 2015-06-22. Zenas BioPharma, is listed under Pharmaceutical Products category by Fama And French industry classification. The fund is listed under Health Care category and is part of Biotechnology family. Zenas BioPharma, Common at this time have 68.18 M in net assets. , while the total return for the last 3 years was -33.04%.
Zenas BioPharma, generates negative cash flow from operations
Check Zenas BioPharma, Probability Of Bankruptcy
Sector Allocation
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Zenas Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Zenas Etf, and the less return is expected.
Institutional investors that are interested in enforcing a sector tilt in their portfolio can use exchange-traded funds, such as Zenas BioPharma, Common Etf, as a low-cost alternative to building a custom portfolio. So, using sector ETFs to diversify your portfolio can be a profitable strategy. However, no matter what sectors are desirable at a given time, no single industry should ever make up more than 20 percent of your stock portfolio.
Zenas BioPharma, Common Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Zenas BioPharma,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.70) | |||
| Total Risk Alpha | (1.25) | |||
| Treynor Ratio | (0.74) |
Zenas BioPharma, Against Markets
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.